Parafibromin - Functional insights

Journal of Internal Medicine

Volumn 266, Issue 1, 2009, Pages 84-98

  Newey, P J ^a   Bowl, M R ^a   Thakker, R V ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Embryonic development; Parafibromin; Parathyroid carcinoma

Indexed keywords

HISTONE; NOTCH RECEPTOR; PARAFIBROMIN; POLYMERASE ASSOCIATED FACTOR 1; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; COMPLEX FORMATION; CONFERENCE PAPER; EMBRYO DEVELOPMENT; EPIGENETICS; FAMILIAL CANCER; FAMILIAL ISOLATED HYPERPARATHYROIDISM; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENETIC CONSERVATION; HETEROZYGOSITY LOSS; HUMAN; HYPERPARATHYROIDISM JAW TUMOR SYNDROME; KIDNEY TUMOR; MAMMAL CELL; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PARATHYROID CARCINOMA; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SIPPLE SYNDROME; TRANSCRIPTION REGULATION; UTERUS TUMOR;

AMINO ACID SEQUENCE; ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERPARATHYROIDISM; JAW NEOPLASMS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASTIC SYNDROMES, HEREDITARY; PARATHYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 66849122011     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02107.x     Document Type: Conference Paper

References (92)

1. Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 2002 17 (Suppl 2 N18 23.
2. Rubin MR, Silverberg SJ. Editorial: HRPT2 in parathyroid cancer: a piece of the puzzle. J Clin Endocrinol Metab 2005 90 : 5505 7.
3. Thakker RV, Juppner H. Genetic disorders of calcium homeostasis caused by abnormal regulation of parathyroid hormaone secretion or responsiveness. In : DeGroot LJ, Jameson JL, eds. Endocrinology. Philadephia, PA : Elsevier, 2006 1511 31.
4. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 2000 343 : 1863 75.
5. Chen JD, Morrison C, Zhang C, Kahnoski K, Carpten JD, Teh BT. Hyperparathyroidism-jaw tumour syndrome. J Intern Med 2003 253 : 634 42.
6. Howell VM, Haven CJ, Kahnoski K et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 2003 40 : 657 63.
7. Carpten JD, Robbins CM, Villablanca A et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002 32 : 676 80.
8. Jackson CE, Norum RA, Boyd SB et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 1990 108 : 1006 12 discussion 12-3.
9. Szabo J, Heath B, Hill VM et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 1995 56 : 944 50.
10. Teh BT, Farnebo F, Kristoffersson U et al. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J Clin Endocrinol Metab 1996 81 : 4204 11.
11. Shattuck TM, Valimaki S, Obara T et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003 349 : 1722 9.
12. Bradley KJ, Hobbs MR, Buley ID et al. Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med 2005 257 : 18 26. (Pubitemid 40129123)
13. Cavaco BM, Barros L, Pannett AA et al. The hyperparathyroidism-jaw tumour syndrome in a Portuguese kindred. QJM 2001 94 : 213 22.
14. Haven CJ, Wong FK, van Dam EW et al. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 2000 85 : 1449 54.
15. Tan MH, Teh BT. Renal neoplasia in the hyperparathyroidism-jaw tumor syndrome. Curr Mol Med 2004 4 : 895 7.
16. Cetani F, Pardi E, Borsari S et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 2004 89 : 5583 91.
17. Cetani F, Pardi E, Ambrogini E et al. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol (Oxf) 2006 64 : 146 52.
18. Moon SD, Park JH, Kim EM et al. A Novel IVS2-1G>A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 2005 90 : 878 83.
19. Bradley KJ, Cavaco BM, Bowl MR, Harding B, Young A, Thakker RV. Utilisation of a cryptic non-canonical donor splice site of the gene encoding Parafibromin is associated with familial isolated primary hyperparathyroidism. J Med Genet 2005 42 : e51.
20. Bradley KJ, Cavaco BM, Bowl MR et al. Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol (Oxf) 2006 64 : 299 306.
21. Mizusawa N, Uchino S, Iwata T et al. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf) 2006 65 : 9 16. (Pubitemid 43911674)
22. Yamashita Y, Akiyama T, Mizusawa N, Yoshimoto K, Goto M. A case of hyperparathyroidism-jaw tumour syndrome found in the treatment of an ossifying fibroma in the maxillary bone. Int J Oral Maxillofac Surg 2007 36 : 365 9.
23. Raue F, Haag C, Frank-Raue K. Hyperparathyroidism-jaw tumor syndrome. A hereditary form of primary hyperparathyroidism with parathyroid carcinoma. Dtsch Med Wochenschr 2007 132 : 1459 62.
24. Masi G, Barzon L, Iacobone M et al. Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocr Relat Cancer 2008 15 : 1115 26.
25. Carlson AL, Smith CL. Primary hyperparathyroidism and jaw tumor syndrome: a novel mutation of the HRPT2 gene. Endocr Pract 2008 14 : 743 7.
26. Bradley KJ, Thakker RV. The hyperparathyroidism-jaw tumour (HPT-JT) syndrome. Clinical Cases in Mineral amd Bone Research 2006 3 : 167 74.
27. Weinstein LS, Simonds WF. HRPT2, a marker of parathyroid cancer. N Engl J Med 2003 349 : 1691 2.
28. Cavaco BM, Guerra L, Bradley KJ et al. Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder mutation of the HRPT2 gene. J Clin Endocrinol Metab 2004 89 : 1747 52.
29. Hobbs MR, Pole AR, Pidwirny GN et al. Hyperparathyroidism-jaw tumor syndrome: the HRPT2 locus is within a 0.7-cM region on chromosome 1q. Am J Hum Genet 1999 64 : 518 25.
30. Teh BT, Farnebo F, Twigg S et al. Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. J Clin Endocrinol Metab 1998 83 : 2114 20.
31. Hobbs MR, Rosen IB, Jackson CE. Revised 14.7-cM locus for the hyperparathyroidism-jaw tumor syndrome gene, HRPT2. Am J Hum Genet 2002 70 : 1376 7.
32. Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ, Simonds WF. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 2005 24 : 1272 6.
33. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971 68 : 820 3.
34. Krebs LJ, Shattuck TM, Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 2005 90 : 5015 7.
35. Zhao J, Yart A, Frigerio S et al. Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene. Oncogene 2007 26 : 3440 9.
36. Zheng HC, Takahashi H, Li XH et al. Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Virchows Arch 2008 452 : 147 55.
37. Selvarajan S, Sii LH, Lee A et al. Parafibromin expression in breast cancer: a novel marker for prognostication? J Clin Pathol 2008 61 : 64 7.
38. Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ et al. The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol 2005 25 : 612 20.
39. Yart A, Gstaiger M, Wirbelauer C et al. The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol 2005 25 : 5052 60.
40. Shi X, Finkelstein A, Wolf AJ, Wade PA, Burton ZF, Jaehning JA. Paf1p, an RNA polymerase II-associated factor in Saccharomyces cerevisiae, may have both positive and negative roles in transcription. Mol Cell Biol 1996 16 : 669 76.
41. Krogan NJ, Kim M, Ahn SH et al. RNA polymerase II elongation factors of Saccharomyces cerevisiae: a targeted proteomics approach. Mol Cell Biol 2002 22 : 6979 92.
42. Mueller CL, Jaehning JA. Ctr9, Rtf1, and Leo1 are components of the Paf1/RNA polymerase II complex. Mol Cell Biol 2002 22 : 1971 80.
43. Squazzo SL, Costa PJ, Lindstrom DL et al. The Paf1 complex physically and functionally associates with transcription elongation factors in vivo. EMBO J 2002 21 : 1764 74.
44. Pokholok DK, Hannett NM, Young RA. Exchange of RNA polymerase II initiation and elongation factors during gene expression in vivo. Mol Cell 2002 9 : 799 809. (Pubitemid 34454890)
45. Wood A, Schneider J, Dover J, Johnston M, Shilatifard A. The Bur1/Bur2 complex is required for histone H2B monoubiquitination by Rad6/Bre1 and histone methylation by COMPASS. Mol Cell 2005 20 : 589 99.
46. Ng HH, Dole S, Struhl K. The Rtf1 component of the Paf1 transcriptional elongation complex is required for ubiquitination of histone H2B. J Biol Chem 2003 278 : 33625 8.
47. Krogan NJ, Dover J, Wood A et al. The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: linking transcriptional elongation to histone methylation. Mol Cell 2003 11 : 721 9.
48. Krogan NJ, Kim M, Tong A et al. Methylation of histone H3 by Set2 in Saccharomyces cerevisiae is linked to transcriptional elongation by RNA polymerase II. Mol Cell Biol 2003 23 : 4207 18.
49. Mueller CL, Porter SE, Hoffman MG, Jaehning JA. The Paf1 complex has functions independent of actively transcribing RNA polymerase II. Mol Cell 2004 14 : 447 56.
50. Lee JS, Shukla A, Schneider J et al. Histone crosstalk between H2B monoubiquitination and H3 methylation mediated by COMPASS. Cell 2007 131 : 1084 96.
51. Sims RJ III., Belotserkovskaya R, Reinberg D. Elongation by RNA polymerase II: the short and long of it. Genes Dev 2004 18 : 2437 68.
52. Nordick K, Hoffman MG, Betz JL, Jaehning JA. Direct interactions between the Paf1 complex and a cleavage and polyadenylation factor are revealed by dissociation of Paf1 from RNA polymerase II. Eukaryot Cell 2008 7 : 1158 67.
53. Penheiter KL, Washburn TM, Porter SE, Hoffman MG, Jaehning JA. A posttranscriptional role for the yeast Paf1-RNA polymerase II complex is revealed by identification of primary targets. Mol Cell 2005 20 : 213 23.
54. Shi X, Chang M, Wolf AJ et al. Cdc73p and Paf1p are found in a novel RNA polymerase II-containing complex distinct from the Srbp-containing holoenzyme. Mol Cell Biol 1997 17 : 1160 9.
55. Betz JL, Chang M, Washburn TM, Porter SE, Mueller CL, Jaehning JA. Phenotypic analysis of Paf1/RNA polymerase II complex mutations reveals connections to cell cycle regulation, protein synthesis, and lipid and nucleic acid metabolism. Mol Genet Genomics 2002 268 : 272 85.
56. Porter SE, Washburn TM, Chang M, Jaehning JA. The yeast pafl-RNA polymerase II complex is required for full expression of a subset of cell cycle-regulated genes. Eukaryot Cell 2002 1 : 830 42.
57. Zhu B, Mandal SS, Pham AD et al. The human PAF complex coordinates transcription with events downstream of RNA synthesis. Genes Dev 2005 19 : 1668 73.
58. Pavri R, Zhu B, Li G et al. Histone H2B monoubiquitination functions cooperatively with FACT to regulate elongation by RNA polymerase II. Cell 2006 125 : 703 17.
59. Mosimann C, Hausmann G, Basler K. Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell 2006 125 : 327 41.
60. Akanuma T, Koshida S, Kawamura A, Kishimoto Y, Takada S. Paf1 complex homologues are required for Notch-regulated transcription during somite segmentation. EMBO Rep 2007 8 : 858 63.
61. Tenney K, Gerber M, Ilvarsonn A et al. Drosophila Rtf1 functions in histone methylation, gene expression, and Notch signaling. Proc Natl Acad Sci USA 2006 103 : 11970 4.
62. Adelman K, Wei W, Ardehali MB et al. Drosophila Paf1 modulates chromatin structure at actively transcribed genes. Mol Cell Biol 2006 26 : 250 60.
63. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005 434 : 843 50.
64. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004 5 : 691 701. (Pubitemid 39150127)
65. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004 20 : 781 810. (Pubitemid 39488658)
66. Bjorklund P, Lindberg D, Akerstrom G, Westin G. Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients. Mol Cancer 2008 7 : 53.
67. Bjorklund P, Akerstrom G, Westin G. An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/beta-catenin signaling. PLoS Med 2007 4 : e328.
68. Bjorklund P, Akerstrom G, Westin G. Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. J Clin Endocrinol Metab 2007 92 : 338 44.
69. Kok FO, Oster E, Mentzer L, Hsieh JC, Henry CA, Sirotkin HI. The role of the SPT6 chromatin remodeling factor in zebrafish embryogenesis. Dev Biol 2007 307 : 214 26.
70. Tan MH, Morrison C, Wang P et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 2004 10 : 6629 37.
71. Bradley KJ, Bowl MR, Williams SE et al. Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal. Oncogene 2007 26 : 1213 21.
72. Agarwal SK, Simonds WF, Marx SJ. The parafibromin tumor suppressor protein interacts with actin-binding proteins actinin-2 and actinin-3. Mol Cancer 2008 7 : 65.
73. Fernandez AG, Gunsalus KC, Huang J et al. New genes with roles in the C. elegans embryo revealed using RNAi of ovary-enriched ORFeome clones. Genome Res 2005 15 : 250 9.
74. Zhang C, Kong D, Tan MH et al. Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochem Biophys Res Commun 2006 350 : 17 24. (Pubitemid 44466569)
75. Iwata T, Mizusawa N, Taketani Y, Itakura M, Yoshimoto K. Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen. Oncogene 2007 26 : 6176 83.
76. Lin L, Czapiga M, Nini L, Zhang JH, Simonds WF. Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism- jaw tumor syndrome enhances its proapoptotic function. Mol Cancer Res 2007 5 : 183 93.
77. Thakker RV. Multiple endocrine neoplasia type 1. In : De Groot LJ, Jameson JL, eds. Endocrinology. Philadephia, PA : Elsevier, 2006 3509 31.
78. Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005 123 : 207 18.
79. Wang P, Bowl MR, Bender S et al. Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult mice. Mol Cell Biol 2008 28 : 2930 40.
80. Constancia M, Dean W, Lopes S, Moore T, Kelsey G, Reik W. Deletion of a silencer element in Igf2 results in loss of imprinting independent of H19. Nat Genet 2000 26 : 203 6.
81. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990 345 : 78 80.
82. Liu JL, Grinberg A, Westphal H et al. Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: manipulation using the Cre/loxP system in transgenic mice. Mol Endocrinol 1998 12 : 1452 62.
83. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993 75 : 59 72.
84. Powell-Braxton L, Hollingshead P, Warburton C et al. IGF-I is required for normal embryonic growth in mice. Genes Dev 1993 7 : 2609 17.
85. Gicquel C, Le Bouc Y. Hormonal regulation of fetal growth. Horm Res 2006 65 (Suppl 3 28 33. (Pubitemid 44689430)
86. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995 376 : 771 4.
87. Foti D, Chiefari E, Fedele M et al. Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat Med 2005 11 : 765 73.
88. Jurisicova A, Antenos M, Kapasi K, Meriano J, Casper RF. Variability in the expression of trophectodermal markers beta-human chorionic gonadotrophin, human leukocyte antigen-G and pregnancy specific beta-1 glycoprotein by the human blastocyst. Hum Reprod 1999 14 : 1852 8.
89. Pampfer S. Apoptosis in rodent peri-implantation embryos: differential susceptibility of inner cell mass and trophectoderm cell lineages - a review. Placenta 2000 21 (Suppl A S3 10.
90. Crabtree JS, Scacheri PC, Ward JM et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 2001 98 : 1118 23.
91. Scacheri PC, Crabtree JS, Kennedy AL et al. Homozygous loss of menin is well tolerated in liver, a tissue not affected in MEN1. Mamm Genome 2004 15 : 872 7.
92. Bolos V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007 28 : 339 63.